NCT07056231 is a NA clinical trial of Caffeine in Caffeine, sponsored by Ulaç Can YILDIRIM.

Who is sponsoring NCT07056231?

NCT07056231 is sponsored by Ulaç Can YILDIRIM.

What drugs are being tested in NCT07056231?

Interventions in NCT07056231: Caffeine, Placebo.

What condition does NCT07056231 study?

NCT07056231 studies Caffeine, Physical Endurance, Muscle Strength, Paralympic Athletes.

Is NCT07056231 still recruiting?

NCT07056231 is currently completed. Last updated 9 July 2025.

Last reviewed 2025-07-09 · How we verify

NCT07056231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Low-Dose Caffeine on Performance in Elite Sitting Volleyball Players

Completed NA Last updated 9 July 2025

What this trial tests

NA trial testing Caffeine in Caffeine in 13 participants. Completed in 12 March 2025.

Timeline

5 March 2025

Primary endpoint
11 March 2025

12 March 2025

Quick facts

Lead sponsor	Ulaç Can YILDIRIM
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	basic science
Enrollment	13
Start date	5 March 2025
Primary completion	11 March 2025
Estimated completion	12 March 2025
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Caffeine (caffeine) — full drug profile →
Placebo

Conditions studied

Caffeine — all drugs for Caffeine →
Physical Endurance — all drugs for Physical Endurance →
Muscle Strength — all drugs for Muscle Strength →
Paralympic Athletes — all drugs for Paralympic Athletes →

Sponsor

Ulaç Can YILDIRIM

Who can join

Adults 18 to 35, male only, with Caffeine or Physical Endurance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Sitting volleyball is a sport that relies primarily on upper body strength and anaerobic capacity. In critical in-game skills such as serve and spike, factors such as speed-endurance time and impact power play a decisive role in performance. There are limited studies in the literature examining the effects of low-dose caffeine consumption on these skills. The effects of ergogenic supplements in Paralympic sports have not been sufficiently investigated, and the potential benefits of caffeine on serve and spike performance in sitting volleyball players remain unclear. Purpose: The main purpose of this research was to determine the effects of low-dose caffeine (3 mg/kg) consumption on the serve speed, spike speed and Speed-Endurance performances of elite-level sitting volleyball players. Method: The study was designed using a randomized, double-blind, balanced, and crossover experimental design. 13 elite male athletes from the 2024 Paravolley European Champion Sitting Volleyball Men's National Team participated in the study. Participants were evaluated for serve speed, spike speed, and speed-endurance performances in both 3 mg/kg caffeine (CAF) and placebo (PLA) conditions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effect of low dose caffeine powder supplementation on serve speed, spike speed, and speed-endurance in elite sitting volleyball players: a randomized double-blind crossover study.
Diedhiou AB, Erkan D, Guler M, Sar H, et al · · 2025 · PMID 41199325 · DOI 10.1186/s13102-025-01408-8

Verify or expand the search:

Other trials of Caffeine

Trials testing the same drug.

NCT07456670 — Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support · Phase 2 · not yet recruiting
NCT07520864 — Effects of Caffeine on Elite Weightlifting Performance · NA · completed
NCT07479875 — Caffeine Supplementation and Strength Endurance in Brazilian Jiu-jitsu Athletes · NA · completed
NCT07466732 — Effects of Caffeine Ingestion on Morning Cognitive and Muscle Repeated Sprint Performance in Males · EARLY_PHASE1 · enrolling by invitation
NCT07458594 — Combined Caffeine and Rhodiola Rosea on Aerial Duel Performance in Soccer · NA · completed

Other recruiting trials for Caffeine

Currently open trials in the same condition.

NCT07469852 — Effects of Caffeine Ingestion on Morning Cognitive and 4-km Time Trial Performance in Males · Phase 1, PHASE2 · active not recruiting
NCT07404254 — Effects of Variations in Caffeinated Beverages on Well-being · NA · recruiting
NCT06763172 — Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI · Phase 4 · recruiting
NCT05325502 — Does Caffeine Facilitate Human Reward Learning Behaviors? · NA · active not recruiting
NCT05454332 — The Caffeine Therapy in the Fetal to Neonatal Transition · Phase 4 · recruiting

Other Ulaç Can YILDIRIM trials

Trials by the same sponsor.

NCT07090421 — Caffeine Dose: Performance and Recovery · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07056231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ulaç Can YILDIRIM
Last refreshed: 9 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07056231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing